重组人表皮生长因子联合曲安奈德治疗糜烂溃疡性口腔黏膜病疗效及安全性评价

Efficacy and Safety of Recombinant Human Epidermal Growth Factor Combined with Triamcinolone Acetonide in the Treatment of Erosive Ulcerative Oral Mucosal Disease

目的探讨重组人表皮生长因子联合曲安奈德治疗糜烂溃疡性口腔黏膜病的临床疗效及安全性。方法选取医院2017年1月至2019年1月收治的患者160例,随机分为观察组和对照组,各53例。对照组患者给予曲安奈德注射液口腔黏膜下注射治疗,在此基础上观察组患者增加重组人表皮生长因子凝胶涂抹治疗。结果观察组总有效率为88.68%,明显高于对照组的71.70%(P<0.05);观察组患者的愈合时间显著短于对照组(P<0.05),转化生长因子-β1(TGF-β1)、血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)水平均高于对照组(P<0.05);治疗后,观察组患者的CD3^+和CD4^+细胞阳性率、CD4^+/CD8^+均明显高于对照组,而CD8+细胞阳性率明显低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(16.98%比9.43%,P>0.05)。结论重组人表皮生长因子联合曲安奈德治疗糜烂溃疡性口腔黏膜病疗效显著,能加速溃疡黏膜愈合,改善生长因子水平和免疫功能,且安全性好。

Objective To investigate the efficacy and safety of recombinant human epidermal growth factor(rhEGF)combined with triamcinolone acetonide in the treatment of erosive ulcerative oral mucosal disease.Methods A total of 106 patients with erosive ulcerative oral mucosal disease treated in the hospital from January 2017 to January 2019 were randomly divided into the observation group and control group,53 cases in each group.The control group was treated with oral submucosal injection of triamcinolone acetonide injection;on this basis,the observation group was added with rhEGF gel.Results The total effective rate of the observation group was 88.68%,which was significantly higher than 71.70%of the control group(P<0.05).The healing time of the observation group was significantly shorter than that of the control group(P<0.05).The levels of transforming growth factor-β1(TGF-β1),vascular endothelial growth factor(VEGF)and basic fibroblast growth factor(bFGF)in the observation group were significantly higher than those in the control group(P<0.05).After treatment,the positive rate of CD3^+,CD4^+cells and the ratio of CD4^+/CD8^+in the observation group were significantly higher than those in the control group,while the positive rate of CD8+cells in the observation group was significantly lower than that in the control group(P<0.05).The incidence of adverse reactions in the observation group and the control group had no statistical difference(16.98%vs 9.43%,P>0.05).Conclusion Recombinant human epidermal growth factor combined with triamcinolone acetonide is effective in the treatment of erosive ulcerative oral mucosal disease.It can accelerate the healing of ulcerative mucosa,improve the level of growth factors,improve the immune function of patients,and has good therapeutic safety.